BefejeződöttFázis nélkül
Expanded Clinical Study of the Tendyne Mitral Valve System
A legfontosabb adatok
- Ki végzi
- Abbott Medical Devices
- Hol
- Atlanta, Clearwater, Cleveland, Dallas, Delray Beach, Detroit, Evanston, Harrisburg, Minneapolis, Morgantown, Roslyn, Scottsdale és Washington D.C. (Egyesült Államok)Mind a 13 helyszín megnézéseMég 9 másik országban, 27 helyszínen
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 191 fő vett részt
- Kezdés
- 2014. nov.
- Befejezés
- 2025. ápr.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Tendyne Mitral Valve System
- A regiszteradat frissítve
- 2025. július 17.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- Severe mitral regurgitation of primary or secondary etiology according to MVARC (Mitral Valve Academic Research Consortium) 2015 defined as:; For Degenerative MR: EROA ≥ 40 mm\^2 or regurgitant volume ≥ 60ml; For Secondary MR: EROA ≥ 20 mm\^2 or regurgitant volume ≥ 30ml
- New York Heart Association (NYHA) functional Class ≥ II while on guideline directed medical therapy (GMDT), including device therapy (CRT) if indicated
- Heart team determines patient is not a suitable candidate for traditional surgical treatment according to valid guidelines
- Age 18 years or older
Ki nem vehet részt
- Prior surgical or interventional treatment of mitral or aortic valves (e.g. valve repair or replacement, MitraClip, edge to edge repair, aortic balloon valvuloplasty, etc.)
- Any planned surgery or interventional procedure within the period of 30 days prior to 30 days following the implant procedure. This includes any planned concomitant cardiovascular procedure such as PCI, pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc
- Cerebrovascular accident (CVA) within six months of planned implant procedure
- Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure
- Participating or planning participation in an investigational drug or another device study
- Patient has a chest condition that prevents transapical access
- Cardiac resynchronization therapy device or implantable pulse generator implanted within three months of planned implant procedure
- Myocardial Infarction (MI) within 30 days of the planned implant procedure
- Symptomatic, unresolved multi-vessel coronary artery disease (CAD) or unprotected left main coronary artery disease requiring stenting or Coronary Artery Bypass Grafting (CABG)
- Severe tricuspid regurgitation, tricuspid valve disease requiring surgery or severe right ventricular dysfunction
- Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
- Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy if cannot be adequately treated
- History of endocarditis within six months of planned implant procedure
- Active systemic infection requiring antibiotic therapy
- Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anti-coagulation therapy) which cannot be adequately managed medically or hypersensitivity to nickel or titanium
- Patient is undergoing hemodialysis due to chronic renal failure
- Patient has pulmonary arterial hypertension (fixed PAS >70mmHg)
- Patients with non-cardiac co-morbidities that are likely to result in a life expectancy of less than one year
- Left ventricular ejection fraction (LVEF) less than 30% by echocardiogram
- Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass
- Left Ventricle (LV) or Left Atrium (LA) thrombus
- Left Ventricular End Diastolic Diameter (LVEDD) > 7.0 cm
- Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound)
- Patient has COPD and is on home oxygen
- Patient refuses blood transfusions
- Pregnant, lactating, or planning pregnancy within next 12 months
- Patient or legal guardian unable or unwilling to give informed consent
- Patient unable or unwilling to comply with study required testing and follow-up visits
Helyszínek itt: Egyesült Államok
Még 9 másik országban, 27 helyszínen
- Emory University HospitalAtlanta, Egyesült Államok
- Morton Plan Mease Health CareClearwater, Egyesült Államok
- Cleveland Clinic FoundationCleveland, Egyesült Államok
- Baylor Heart & Vascular CenterDallas, Egyesült Államok
- Delray Medical CenterDelray Beach, Egyesült Államok
- Henry Ford HospitalDetroit, Egyesült Államok
- Northshore University Health SystemEvanston, Egyesült Államok
- Pinnacle Health - Harrisburg HospitalHarrisburg, Egyesült Államok
- Abbott-Northwestern HospitalMinneapolis, Egyesült Államok
- West Virginia UniversityMorgantown, Egyesült Államok
- St. Francis HospitalRoslyn, Egyesült Államok
- Honor Health Scottsdale Shea Medical CenterScottsdale, Egyesült Államok
- MedStar Washington HospitalWashington D.C., Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to evaluate the safety and performance of the Tendyne Mitral Valve System in the treatment of severe mitral regurgitation in patents with functional disability greater than or equal to NYHA Class II, who are not suitable candidates for surgical replacement with otherwise available devices. Follow-up evaluations will be conducted through 5 years post implantation.
A vizsgálat csoportja
- Tendyne Mitral Valve SystemA vizsgált kezelés
Patients will undergo transcatheter mitral valve replacement
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Publikációk
- 2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation.Journal of the American College of Cardiology, 2021
- Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation: A Global Feasibility Trial.Journal of the American College of Cardiology, 2017
- A regiszteradat frissítve
- 2025. július 17.